Publications of Roman K. Thomas
All genres
Journal Article (72)
2009
Journal Article
4 (9), p. S800 - S800 (2009)
Chemical genomics of RAD001 in non-small cell lung cancer. Journal of Thoracic Oncology
Journal Article
34 (2), pp. 489 - 506 (2009)
High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. European Respiratory Journal
Journal Article
119 (6), pp. 1727 - 1740 (2009)
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. Journal of Clinical Investigation
Journal Article
69 (8), pp. 3256 - 3261 (2009)
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research
Journal Article
25 (6), pp. 722 - 728 (2009)
A flexible rank-based framework for detecting copy number aberrations from array data. Bioinformatics
Journal Article
106 (12), pp. 4834 - 4839 (2009)
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America
Journal Article
4 (10), p. e7273 - e7273 (2009)
High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-lGF-1R antibody (R1507). PLoS ONE
Journal Article
50 (11), pp. 1815 - 1819 (2009)
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. Journal of Nuclear Medicine 2008
Journal Article
3 (12), p. e3908 - e3908 (2008)
Early detection of erlotinib treatment response in NSCLC by 3'-Deoxy-3'-[18F]-fluoro-L-thymidine ([18F]FLT) positron emission tomography (PET). PLoS ONE
Journal Article
9, p. Art.Nr. 475 (2008)
Standardized high-throughput evaluation of cell-based compound screens. BMC Bioinformatics
Journal Article
455 (7216), pp. 1069 - 1075 (2008)
Somatic mutations affect key pathways in lung adenocarcinoma. Nature
Journal Article
68 (14), pp. 5524 - 5528 (2008)
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Research
Journal Article
14 (13), pp. 4275 - 4283 (2008)
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clinical Cancer Research
Journal Article
68 (14), pp. 5827 - 5838 (2008)
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Research
Journal Article
68 (3), pp. 664 - 673 (2008)
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Research
Journal Article
3 (2), pp. 170 - 173 (2008)
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway. Journal of Thoracic Oncology 2007
Journal Article
450 (7171), pp. 893 - 898 (2007)
Characterizing the cancer genome in lung adenocarcinoma. Nature
Journal Article
104 (50), pp. 20007 - 20012 (2007)
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America
Journal Article
2 (8), pp. S381 - S382 (2007)
Translational lung cancer genomics. Journal of Thoracic Oncology
Journal Article
26 (34), pp. 5023 - 5027 (2007)
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ ERBB2 inhibitor HKI-272. Oncogene